SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (1481)3/10/2000 10:14:00 AM
From: Torben Noerup Nielsen  Read Replies (1) | Respond to of 2001
 
John,

I agree. That's why I'm quite long GLIA :-) Despite all the noise from the shorts. Eventually, they'll have to go away and leave this one alone. It just burns me to see them get a chance to get out so easily after all the problems they've caused. But that's business.

Thanks, Torben



To: Dr. John M. de Castro who wrote (1481)3/10/2000 12:05:00 PM
From: Biomaven  Read Replies (2) | Respond to of 2001
 
John,

But note that the ALXN complement inhibitor program is already partnered and well into the clinic. So GLIA is well behind on this one, although there may well be room for more than one drug even if the ALXN drug works out.

BTW, at the ALXN website

alxn.com

there is a very nice picture-show of the complement cascade (needs flash plug-in).

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News